Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016

This research article reports patients in the CHOP- tositumomab arm had significantly better 10-year progression-free survival compared with patients in the CHOP-rituximab arm (56% v 42%; P=0.01), but 10-year overall survival was not different between the two arms (75% v 81%; P=0.13)

Source: Current Awareness Service for Health (CASH) - January 25, 2018 Category: Consumer Health News Source Type: news